Suzhou Basecare Medical Corporation Limited (2170.HK)

HKD 2.75

(-8.94%)

Market Cap (In HKD)

819.87 Million

Revenue (In HKD)

207.97 Million

Net Income (In HKD)

-191.68 Million

Avg. Volume

67.22 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.29-3.82
PE
-
EPS
-
Beta Value
0.144
ISIN
CNE100004BC1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Bo Liang Ph.D.
Employee Count
-
Website
https://www.basecare.cn
Ipo Date
2021-02-08
Details
Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.